Aldosterone Breakthrough for the Prediction of Treatment Response to Mineralocorticoid Receptor Antagonists
Chronic kidney disease (CKD) is one of the leading causes of morbidity and mortality.1 Aldosterone is considered one of its key pathophysiological mediators, supporting the use of mineralocorticoid receptor antagonists (MRAs) for the treatment of CKD and concomitant cardiovascular disease.2-4
Authors
- Caroline Najjar
- Abhinav Sharma (ORCID: https://orcid.org/0000-0002-2346-8330)
- Pedro Marques (ORCID: https://orcid.org/0000-0002-1120-5461)
- Ahmed Imcaoudene
- Michael A. Tsoukas (ORCID: https://orcid.org/0000-0002-8326-7274)
- Thomas A. Mavrakanas (ORCID: https://orcid.org/0000-0002-3368-247X)
Institutions
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1016/j.xkme.2025.101040
- Citations
- 1
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- McGill University
- Novo Nordisk
- Servier
- Bristol-Myers Squibb Canada